Skip to main content

Maze Therapeutics, Inc.

corporate_fare Company Profile

Maze Therapeutics, Inc.

MAZE·NASDAQ·Life Sciences·CIK 0001842295

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses human genetics to develop small molecule precision medicines for kidney and metabolic diseases. The company uses its Compass platform to identify and characterize genetic variations linked to health and disease, and then determines how these variations contribute to disease risk or protection in specific patient groups through a process called variant functionalization. The Compass platform is designed to inform all stages of drug discovery, development, and clinical trial design. Maze Therapeutics, Inc. is currently advancing two wholly-owned clinical programs: MZE829 and MZE782. Its most advanced program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1 (APOL1) for treating APOL1-mediated kidney disease (AMKD), a genetically defined type of chronic kidney disease (CKD) that currently has no approved treatment. In October 2024, the company reported results from its Phase 1 clinical trial of MZE829, which enrolled 111 healthy adult volunteers. MZE829 was well tolerated and showed dose-proportional pharmacokinetics (PK). A Phase 2 trial of MZE829 began in November 2024, with the first patient dosed in February 2025. In March 2026, positive topline clinical proof of concept data were reported from this open-label study, which enrolled 15 patients. All 15 patients were included in a safety and tolerability analysis, and 12 were evaluable for efficacy. MZE829 was well tolerated, and treatment resulted in a mean reduction in urinary albumin-to-creatinine ratio (uACR) of 35.6% at week 12 in evaluable patients with broad AMKD, with 50% of these patients achieving at least a 30% reduction in uACR. In a subset of patients with focal segmental glomerulosclerosis (FSGS), the mean uACR reduction was 61.8%. Treatment of non-diabetic AMKD patients with MZE829 led to a mean reduction from baseline uACR of 48.6%. The company plans to continue enrollment in the Phase 2 trial and advance MZE829 into a pivotal development program.

Maze Therapeutics, Inc. (NASDAQ:MAZE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for MAZE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MAZE spans 10-Q, 8-K, 424B5, 10-K.

Recent high-impact activity:

  • Maze Q3 Loss Widens to $48M, Missing Estimates on R&D Costs
  • Vertex Kidney Drug Data Sparks 22% Surge in Maze Therapeutics
  • Maze Therapeutics Q2 2026: Net Loss Widens to $44.7M, Cash Runway Extended with $494.9M in Reserves
  • Maze Therapeutics Q2 2026: Wider Loss Offset by Pipeline Progress and Cash Runway into 2029
  • Q1 Net Loss Beats Estimates, $144.7M Offering & $20M Milestone Extend Cash Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$131.12M
Diluted EPS
-$3.05
Op. Cash Flow
-$111.94M
Free Cash Flow
-$112.73M
Operating Income
-$142.9M
Cash & Equivalents
$189.25M
Debt / Equity
0.00×
Shares Outstanding
49.34M sh
Source: 10-K · filed 2026-03-25 · accession 0001193125-26-122778

Short Interest & Short Volume

8.76 days to cover

FINRA reported short interest of 6,684,604 shares in MAZE as of the October 30, 2026 settlement, a 11.2% decrease from the prior period — about 8.8 days to cover at its recent average daily volume. On November 20, 2026, 65.4% of MAZE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,684,604 shares as of October 30, 2026
Change vs prior period▼ 11.2%
Days to cover8.76 at avg daily volume of 763,468
Daily short volume (FINRA facilities)65.4% of 311,039 shares on November 20, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$31.37
52-week range · as of 2026-08-11 $12.81 – $53.65
Market cap
$1.72B
Volume
818.9K (1.1× avg)
3-mo avg 744.6K
Live data · 2026-11-21 11:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MAZE - Latest Insights

MAZE
Nov 09, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $34.91
Real-time Price: $31.37 info
Change: -$3.54 (-10%) info
Market Cap: $1.715B info
MAZE
Sep 22, 2026, 12:47 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $27.20
Real-time Price: $31.37 info
Change: +$4.18 (+15%) info
Market Cap: $1.715B info
MAZE
Aug 11, 2026, 4:48 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.50
Real-time Price: $31.37 info
Change: +$3.87 (+14%) info
Market Cap: $1.715B info
MAZE
Aug 11, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.50
Real-time Price: $31.37 info
Change: +$3.87 (+14%) info
Market Cap: $1.715B info
MAZE
May 12, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.78
Real-time Price: $31.37 info
Change: +$5.59 (+22%) info
Market Cap: $1.715B info
MAZE
May 12, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $25.78
Real-time Price: $31.37 info
Change: +$5.59 (+22%) info
Market Cap: $1.715B info
MAZE
Apr 22, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $26.50
Real-time Price: $31.37 info
Change: +$4.87 (+18%) info
Market Cap: $1.715B info
MAZE
Apr 22, 2026, 4:53 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $26.50
Real-time Price: $31.37 info
Change: +$4.87 (+18%) info
Market Cap: $1.715B info
MAZE
Apr 22, 2026, 12:11 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $25.69
Real-time Price: $31.37 info
Change: +$5.68 (+22%) info
Market Cap: $1.715B info
MAZE
Mar 25, 2026, 7:11 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $49.00
Real-time Price: $31.37 info
Change: -$17.63 (-36%) info
Market Cap: $1.715B info
MAZE
Mar 25, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $49.00
Real-time Price: $31.37 info
Change: -$17.63 (-36%) info
Market Cap: $1.715B info
MAZE
Feb 04, 2026, 5:17 PM EST
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $48.14
Real-time Price: $31.37 info
Change: -$16.77 (-35%) info
Market Cap: $1.715B info
MAZE
Feb 04, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.14
Real-time Price: $31.37 info
Change: -$16.77 (-35%) info
Market Cap: $1.715B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets